31 results about "Pluronic F68" patented technology

The present invention relates to the field of pharmaceutical preparations of follicle stimulating hormone (FSH), luteinizing hormone (LH) and mixtures of FSH and LH and methods for the production of these preparations. The present invention also provides liquid or lyophilized formulations of FSH, or LH, or FSH and LH, which contain a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.

The invention discloses a Chinese hamster ovary culture medium as well as a preparation method and application thereof. The culture medium comprises ascorbic acid, pyridoxine hydrochloride, vitamin B12, nicotinamide, riboflavin, thiamine chloride, choline chloride, folic acid, calcium pantothenate, sodium pyruvate, reduced glutathione, inositol, biotin, hypoxanthine, putrescine, lipoic acid, linoleic acid, thymine, glucose, HEPES (2-hydroxyethyl) buffer solution, dextran sulphate, Pluronic-F68, various amino acids and salts thereof and various inorganic salts. The culture medium has low cost, and the component does not contain animal origin ingredients, does not contain protein and has definite chemical ingredients. All ingredients are cooperated and blended, and the Chinese hamster ovary culture medium can satisfy the basic growth requirement of cells, and can effectively regulate, transfer and control the culture of cells so as to realize good high-density cell culture. Compared with the culture effect of the existing culture medium, the culture effect of culture medium disclosed in the invention is at least equivalent to even superior to the existing culture medium.

A drug carrier with thermal sensitivity, a manufacturing method thereof, and a use thereof are disclosed. The drug carrier comprises a nano-magnetic particle, a drug, a composite polymer, and a dense silica shell. The nano-magnetic particle and the drug are encapsulated in the composite polymer which is formed by self-assembly a water-soluble polymer (such as poly vinyl alcohol) and a thermosensitive copolymer (such as Pluronic F68 or Pluronic F127). The stability and drug release of the drug carrier a can be adjusted by combining PVA and thermosensitive copolymer with a different ratio. When an external magnetic field was applied, the cores exhibit significant size shrinkage and the diameter of the drug carrier decreases more than 10 folds due to the change of temperature, which causes burst-like drug release because of shell destruction and physical collapse of the drug carrier.

The invention discloses a kit for single cell genome-wide amplification and application thereof. The invention protects a kit for single cell genome amplification first, comprising a second amplification system; the second amplification system is composed of 10*Phi29buffer, water and a first amplification system; the first single amplification system is composed of dNTP (1.8-2.2)*10-8 mol, N8 primers (1.8-2.2)*10-11 mol in total concentration, BSA (4.5-5.5)*10-3 mg, Pluronic F68 0.0045-0.0055Mul, and DNA polymerase 9-11 U Phi29; the N8 primers are random primers, composed of eight deoxyribonucleotides, in a random arrangement of A, G, C and T. The WGA kit low in cost, high in efficiency and stable in amplification effect is developed based on the multiple exchange amplification principle and amplification features of DNA polymerase Phi29, and the kit has an important applicable prospect and polarization value.

The invention discloses a preparation technology and application of paeoniflorin wheat gliadin nanoparticles. After gluten flour is subjected to degreasing, ethyl alcohol is added for extraction, an extracting solution is concentrated, and freeze drying is performed to obtain wheat gliadin; the wheat gliadin and paeoniflorin of the formula are weighed, ethyl alcohol is added for dissolution, the ethyl alcohol mixture solution is injected into a pluronic F68 or PVA-0486 solution, stirring is performed to obtain a colloid dispersion solution, and then freeze drying is performed to obtain paeoniflorin wheat gliadin nanoparticles. A nano-carrier is edible wheat gliadin and is free of toxicity, easy to obtain and low in production cost. The prepared paeoniflorin wheat gliadin nanoparticles can be independently used or be compatible with other medicines to prepare a preparation, absorption of paeoniflorin inside a human body is improved, the defect that the biological availability of paeoniflorin is poor is overcome, the medicine effect of paeoniflorin can be greatly improved, and the dosage is reduced.

The invention discloses an allicin fat emulsion injection and a preparation process thereof; the invention is the drug which is made by the materials with the following mix ratios by weight, while the pH value of which is 6.5 to 7.5, the average particle size of the emulsion particles is 200nm, and the particle size thereof is 100 to 300nm and the Zeta potential is minus 50 to 80mv. The raw materials are: allicin, egg yolk lecithin, pluronic F68, oleic acid, and injection water and so on. The preparation process is that the egg yolk lecithin, oleic acid, vitamin E and soya bean oil are taken at first under the aseptic conditions for mixing, heating, agitating and dissolving, then the allicin is added to agitate till dissolution, and the filtrate can be obtained after the pressure filtration by a microporous membrane; the glycerol is taken at first and the injection water, disodium ethylene diamine tetraacetate and pluronic F68 are added for mixing and agitating till the dissolution, then the filtrate can be obtained after the pressure filtration by the microporous membrane; after the mixture of the two filtrates, a high speed agitator is used for agitating, the product is finally obtained through a high pressure homogenizer. The invention is characterized by no irritating effect and good stability, etc.

The invention discloses an oxaliplatin-and-irinotecan jointly loading lipid emulsion prepared based on the drug lipid composite technology. The oxaliplatin-and-irinotecan jointly loading lipid emulsion is prepared from oxaliplatin with the concentration of 0.5 mg/ml-2 mg/ml, irinotecan with the concentration of 0.5 mg/ml-5 mg/ml, 5%-20% of injection oil, 0.5%-2.5% of phospholipid, 0.1%-2% of pluronic F68, 0.01%-0.5% of a stabilizing agent, 0.1%-2.5% of glycerol and water. By means of the jointly-loading lipid emulsion prepared with the drug lipid composite technology, synchronous releasing of two drugs in the human body can be coordinated, it is guaranteed that the two drugs are kept in the optimized dosage ratio when reaching the tumor site, and therefore the best collaborative effect is achieved.

The invention relates to the technical field of medicines, provides a nano-scale delivery system loading two surfactants and having anti-tumor-drug-resistance, and further provides a preparation method of the nano-scale delivery system and application of the nano-scale delivery system in preparation of anti-tumor medicines. Two surfactants loaded in the drug-loaded nano-particles are Pluronic L61 and Pluronic F68, wherein Pluronic L61 has excellent anti-drug-resistance and excellent biocompatibility, has the activity independent of types of chemotherapeutic drugs and tumors and can be widely applied to chemosensitization of multiple tumors and Pluronic F68 has excellent water solubility and safety, is capable of remarkably improving stability of nano-particles in water and guaranteeing in-vivo long circulation of the nano-particles to reach tumor tissues and further has an effect of freeze-drying protection and no extra freeze-drying protective additive needs to be added.

The invention discloses a propofol microemulsion composition which does not contain phosphatide and fatty acid triglycerides. The propofol microemulsion composition provided by the invention comprises 0.8-1.2 % (w/v) of propofol, 20-25 % (w/v) of Pluronic F 68, 20-30 % (w/v) of propylene glycol and the balance being water. The invention provides the propofol microemulsion composition which can be administered through gastrointestinal tracts, skins, mucous membranes or injection, and the composition has advantageous of simple technology conditions, greatly improved stability and convenient usage, and is easy to realize productization and be clinically accepted.

The invention discloses nimodipine long-acting oral suspension liquid and a preparation method thereof. The nimodipine long-acting oral suspension liquid is prepared from the following components in parts by weight: 0.1 to 0.3 part of nimodipine nano-particle, 0.1 to 0.3 part of nimodipine, 0.1 to 2 parts of sweetening agent, 1 to 5 parts of pH buffering agent, 0.1 to 2 parts of preservative and 90 to 100 parts of solvent. A carrier material of the nimodipine nano-particle is a combinant of polylactic acid-hydroxyacetic acid copolymer and pluronic F68, and the pluronic F68 is 5 to 40 percent by mass of the carrier material. The nimodipine long-acting oral suspension liquid disclosed by the invention is convenient to orally take and has a good taste; a part of medicines exists in a free state, so that absorption speed can be accelerated and an effect takes quickly; a part of medicines are carried in the polylactic acid-hydroxyacetic acid copolymer and pluronic F68 nano-particles, so that a first pass effect can be reduced, a medicine utilization ratio is high, the drug load of the nano-particles is large, an entrapment ratio is high, release is slow, the acting time is long, the administration frequency is reduced, the defect of existing marketed dosage forms is overcome; the preparation method has the advantages of good reproducibility, good repeatability, and easiness for being strongly implemented and popularized on the industry.

The invention relates to the technical field of stem cells, in particular to a serum-free culture medium of placental mesenchymal stem cells. The serum-free culture medium of the placental mesenchymalstem cells comprises a DMEM low-sugar culture medium and a supplement, wherein the supplement comprises the following components: human serum albumin with a concentration of 1-5 mg/mL, transferrin with a concentration of 5-10 [mu]g/mL, an epidermal growth factor with a concentration of 5-10 ng/mL, a transforming growth factor with a concentration of 10-30 ng/mL, a platelet-derived growth factor with a concentration of 10-25 ng/mL, glutathione with a concentration of 1-5 [mu]g/mL, Pluronic F68 with a concentration of 10-20 [mu]g/mL and lignans with a concentration of 5-10 [mu]g/mL. The produced serum-free culture medium can significantly improve the proliferation capability of the placental mesenchymal stem cells, a survival rate of the placental mesenchymal stem cells is high, the culturecost is low, the culture time of the cells is shortened, the application range is wide, and the serum-free culture medium of the placental mesenchymal stem cells can be used for industrial production.

The invention provides a naringenin nano lipid carrier as well as a preparation method and application thereof. The naringenin nano lipid carrier comprises naringenin and a nano lipid carrier. When the naringenin nano lipid carrier is prepared by using a rotational evaporation method, the nano lipid carrier comprises phospholipid, glycerol trilaurate, medium chain triglyceride and polyoxyethylatedcastor oil; and when the naringenin nano lipid carrier is prepared by using an emulsification evaporation-low temperature curing method, the nano lipid carrier comprises phospholipid, glyceryl monostearate, stearic acid, oleic acid and pluronic F68. The naringenin nano lipid carrier provided by the invention has high encapsulation efficiency and a large medicine carrying capacity, and the orallytaken bioavailability of naringenin can be improved. Compared with free naringenin and a naringenin nano lipid of a reference file 3, the naringenin nano lipid carrier prepared by using the emulsification evaporation-low temperature curing method has higher trans-enterocyte single-layer transfer efficiency and better small intestine absorption effects. Therefore, the carrier has a good inhibitionfunction on non-alcoholic fatty liver diseases with a small dosage.

The invention discloses a culture medium additive for promoting protein expression, and belongs to the technical field of cell culture. The culture medium additive comprises vitamin C, ethanolamine, L-asparagine, L-cysteine hydrochloride, L-cystine dihydrochloride, L-proline, L-tryptophan, soy peptone, N-acetylcysteine and pluronic F68. The culture medium additive for promoting protein expression is added into DMEM, DMEM/F12 and RPMI1640 basic culture media, so that the yield of cell expression protein can be increased, and a foundation is laid for improving protein antibody drugs.